- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05785195
A Mechanistic Study of Inhaled Nitric Oxide in COPD
May 12, 2023 updated by: Ting YANG
Study on the Mechanism of Inhaled Nitric Oxide in the Treatment of Patients With Chronic Obstructive Pulmonary Disease (COPD) Complicated With Pulmonary Hypertension
There is a lack of effective treatments for chronic obstructive pulmonary disease (COPD) complicated with pulmonary hypertension.
Previous studies have found that inhaled nitric oxide (iNO) can reduce pulmonary artery pressure and improve exercise capacity in COPD with pulmonary hypertension patients.
However, the specific mechanism is unclear.
The study aims to evaluate pulmonary ventilation/perfusion, pulmonary artery pressure, oxygenation, symptoms and quality of life in COPD with pulmonary hypertension patients after short-term treatment with iNO.
Observing a series of pathophysiological changes caused by the treatment of pulmonary hypertension with iNO in COPD, the investigators hope to provide new theoretical basis and research ideas.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhou Fang
- Phone Number: +8615655595707
- Email: zhou.fang@novlead.com
Study Contact Backup
- Name: Ruoxi He
- Phone Number: +8618874167666
- Email: heruoxi1985@yeah.net
Study Locations
-
-
-
Beijing, China
- Recruiting
- China-Japan Friendship Hospital
-
Contact:
- Ke HUANG, M.D.
- Phone Number: 010-84206408
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥ 40 years, ≤ 75 years
- Currently smoking or former smokers with at least 10 pack-years of tobacco cigarette smoking history
- Diagnosis of moderate and severe COPD by the Global initiative for chronic Obstructive Lung Disease (GOLD) 2022 criteria: A post-bronchodilatory forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) < 0.7, and 30%< FEV1 < 80% predicted
- Echocardiogram with technical adequacy demonstrating with Pulmonary Hypertension: Tricuspid regurgitation velocity (TRV) > 2.8 m/s or pulmonary arterial systolic pressure (sPAP) ≥38mmHg
- Signed informed consent prior to the initiation of any study mandated procedures or assessments
Exclusion Criteria:
- Experienced an exacerbation requiring start of or increase in systemic oral corticosteroid therapy during the last month
- Treatment with antibiotics
- Respiratory failure requiring supplemental oxygen therapy
- A diagnosis of Interstitial lung disease, asthma, tuberculosis, bronchiectasis, pneumonia, lung cancer, pulmonary embolism, or other non-COPD respiratory disease
- Any history of lung resection
- Left ventricular dysfunction: left ventricular ejection fraction (LVEF) < 40%
- Clinically significant valvular heart disease, including aortic valvular disease (moderate or greater aortic stenosis or regurgitation) and/or mitral valve disease (moderate or greater mitral stenosis or regurgitation), or status post mitral valve replacement
- Use within 30 days of screening or current use of approved PH medications such as sildenafil, bosentan or prostacyclines
- Neuromuscular disease or musculoskeletal injuries that unable to complete exercise trials
- Use of investigational drugs or devices within 30 days prior to enrollment into the study
- Any underlying medical or psychiatric condition that, in the opinion of the Investigator, makes the subject an unsuitable candidate for the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inhaled Nitric Oxide (iNO)
iNO 20ppm,≥8 hours/day for 3 days
|
The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ventilation-perfusion ratio
Time Frame: Baseline, Minutes 30
|
Change in ventilation-perfusion ratio (V/Q) from Baseline after treatment with iNO, measured by pulmonary ventilation/perfusion imaging
|
Baseline, Minutes 30
|
Tricuspid regurgitation velocity (TRV)
Time Frame: Baseline, Day 3
|
Change in TRV from Baseline after treatment with iNO, measured by echocardiogram
|
Baseline, Day 3
|
Pulmonary arterial systolic pressure (sPAP)
Time Frame: Baseline, Day 3
|
Change in sPAP from Baseline after treatment with iNO, measured by echocardiogram
|
Baseline, Day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulmonary function:Forced expiratory volume in 1 second(FEV1)
Time Frame: Baseline, Day 3
|
Change in FEV1 from Baseline after treatment with iNO
|
Baseline, Day 3
|
Pulmonary function: Forced vital capacity (FVC)
Time Frame: Baseline, Day 3
|
Change in FVC from Baseline after treatment with iNO
|
Baseline, Day 3
|
Pulmonary function: FEV1/FVC
Time Frame: Baseline, Day 3
|
Change in ratio of FEV1 and FVC (FEV1/FVC) from Baseline after treatment with iNO
|
Baseline, Day 3
|
Pulmonary function: Diffusion lung capacity for carbon monoxide(DLCO)
Time Frame: Baseline, Day 3
|
Change in DLCO from Baseline after treatment with iNO
|
Baseline, Day 3
|
Cardiopulmonary Exercise Test: Maximal oxygen uptake(VO2max)
Time Frame: Baseline, Day 3
|
Change in VO2max from Baseline after treatment with iNO
|
Baseline, Day 3
|
Cardiopulmonary Exercise Test: Anaerobic threshold(AT)
Time Frame: Baseline, Day 3
|
Change in AT from Baseline after treatment with iNO
|
Baseline, Day 3
|
Cardiopulmonary Exercise Test: Minute ventilation-to-carbon dioxide output(VE/VCO2)
Time Frame: Baseline, Day 3
|
Change in VE/VCO2 from Baseline after treatment with iNO
|
Baseline, Day 3
|
Cardiopulmonary Exercise Test: Physiological dead space ventilation (physiological deadspace volume/tidal volume, Vd/Vt)
Time Frame: Baseline, Day 3
|
Change in Vd/Vt from Baseline after treatment with iNO
|
Baseline, Day 3
|
Six-minute walk distance (6MWD)
Time Frame: Baseline, Day 3
|
Change in 6MWD from Baseline after treatment with iNO
|
Baseline, Day 3
|
Arterial blood gas: Arterial partial pressure of oxygen (PaO2)
Time Frame: Baseline, Day 3
|
Change in PaO2 from Baseline after treatment with iNO
|
Baseline, Day 3
|
Arterial blood gas: Arterial partial pressure of carbon dioxide (PaCO2)
Time Frame: Baseline, Day 3
|
Change in PaCO2 from Baseline after treatment with iNO
|
Baseline, Day 3
|
Arterial blood gas: Alveolar-arterial oxygen partial pressure difference (A-aDO2)
Time Frame: Baseline, Day 3
|
Change in A-aDO2 from Baseline after treatment with iNO
|
Baseline, Day 3
|
Life quality and symtom severity questionnaires: COPD assessment test (CAT)
Time Frame: Baseline, Day 3
|
Change in CAT scores (0-40 scores, higher scores mean a worse outcome) from Baseline after treatment with iNO
|
Baseline, Day 3
|
Life quality and symtom severity questionnaires: Modified Medical Research Council (mMRC) Dyspnea Scale
Time Frame: Baseline, Day 3
|
Change in (mMRC) Dyspnea Scale scores (0-4 scores, higher scores mean a worse outcome) from Baseline after treatment with iNO
|
Baseline, Day 3
|
Life quality and symtom severity questionnaires: Saint George Respiratory Questionnaire (SGRQ)
Time Frame: Baseline, Day 3
|
Change in SGRQ scores (0-100 scores, higher scores mean a worse outcome) from Baseline after treatment with iNO
|
Baseline, Day 3
|
Adverse events
Time Frame: Baseline up to Day 3
|
Incidence of adverse events = Number of subjects with adverse events/Total number of subjects in treatment×100%
|
Baseline up to Day 3
|
Percutaneous arterial oxygen saturation (SpO2)
Time Frame: Baseline, Day 3
|
Change in SpO2 from Baseline after treatment with iNO
|
Baseline, Day 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 14, 2023
Primary Completion (Anticipated)
December 31, 2023
Study Completion (Anticipated)
March 31, 2024
Study Registration Dates
First Submitted
February 17, 2023
First Submitted That Met QC Criteria
March 14, 2023
First Posted (Actual)
March 27, 2023
Study Record Updates
Last Update Posted (Actual)
May 15, 2023
Last Update Submitted That Met QC Criteria
May 12, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Hypertension
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Hypertension, Pulmonary
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Protective Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Antioxidants
- Free Radical Scavengers
- Endothelium-Dependent Relaxing Factors
- Gasotransmitters
- Nitric Oxide
Other Study ID Numbers
- 2022-HX-110
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Nitric Oxide Generation and Delivery System
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedPulmonary HypertensionUnited States
-
The First Affiliated Hospital with Nanjing Medical...Novlead Inc.RecruitingChronic Obstructive Pulmonary DiseaseChina
-
Beyond Air Inc.WithdrawnCOVID-19 | Pneumonia, Viral | SARS-CoV 2 | Corona Virus Infection | Respiratory Disease
-
Xijing HospitalMassachusetts General Hospital; Fondazione IRCCS Ca' Granda, Ospedale Maggiore...WithdrawnSARS (Severe Acute Respiratory Syndrome) | Coronavirus Covid-19 Infection Variant Omicron
-
Beyond Air Inc.Recruiting
-
Tomsk National Research Medical Center of the Russian...Siberian State Medical UniversityCompletedCoronavirus Infection | Pneumonia, Viral | HypoxemiaRussian Federation
-
Novlead Inc.RecruitingPulmonary Hypertension of NewbornChina
-
BellerophonCompletedChronic Obstructive Pulmonary Disease | Idiopathic Pulmonary Fibrosis | Pulmonary HypertensionBelgium
-
Geno LLCCompletedPulmonary Arterial HypertensionUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyocardial Ischemia | Coronary DiseaseUnited States